• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket

    9/21/23 7:51:35 AM ET
    $AEHL
    $AENT
    $ARBB
    $AVGR
    Building Materials
    Industrials
    Durable Goods
    Consumer Discretionary
    Get the next $AEHL alert in real time by email

    Gainers

    Near Intelligence, Inc. (NASDAQ:NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to also serve as the company’s Chief Privacy Officer.

    Neptune Wellness Solutions Inc. (NASDAQ:NEPT) shares rose 28.5% to $5.03 in pre-market trading after falling 11% on Wednesday. Neptune Wellness announced intention to spinout Sprout Organics pursuant to the Morgan Stanley agreed to transaction.

    Murphy Canyon Acquisition Corp. (NASDAQ:MURF) shares rose 32.4% to $17.00 in pre-market trading. Murphy Canyon Acquisition reported stockholder approval of the proposed combination with Conduit Pharmaceuticals.

    TradeUP Acquisition Corp. (NASDAQ:UPTD) shares jumped 24.2% to $15.22 in pre-market trading after surging 26% on Wednesday. The company announced an extension for its initial business combination deadline, depositing an aggregate of $37,432.70 into its trust account.

    Alliance Entertainment Holding Corporation (NASDAQ:AENT) shares gained 19.8% to $1.27 in pre-market trading after falling 25% on Wednesday.

    Antelope Enterprise Holdings Limited (NASDAQ:AEHL) rose 19.4% to $3.50 in pre-market trading. Antelope Enterprise announced a one-for-ten reverse stock split.

    Fresh Vine Wine, Inc. (NYSE:VINE) rose 14.7% to $0.5390 in pre-market trading after gaining over 5% on Wednesday.

    MSP Recovery, Inc. (NASDAQ:LIFW) shares surged 14.3% to $0.1758 in pre-market trading after jumping 64% on Wednesday.

    Kezar Life Sciences, Inc. (NASDAQ:KZR) gained 13.2% to $1.29 in pre-market trading. Kezar Life Sciences and Everest Medicines collaborated to bring zetomipzomib to patients with lupus nephritis and more across Greater China, South Korea, and Southeast Asia.

    Cardiol Therapeutics Inc. (NASDAQ:CRDL) shares climbed 9.1% to $1.08 in pre-market trading.

    Losers

    TransCode Therapeutics, Inc. (NASDAQ:RNAZ) fell 16.1% to $0.5540 in pre-market trading after jumping more than 25% on Wednesday.

    Akerna Corp. (NASDAQ:KERN) shares fell 13.1% to $0.20 in pre-market trading.

    ARB IOT Group Limited (NASDAQ:ARBB) fell 13% to $1.81 in pre-market trading.

    Avinger, Inc. (NASDAQ:AVGR) fell 12.2% to $12.11 in pre-market. Avinger said on Sept. 18, 2023, the company increased the amount available for sale by up to an additional aggregate offering price of $2,133,181.

    Fitell Corporation (NASDAQ:FTEL) shares fell 11.7% to $2.34 in pre-market trading. Fitell Corporation, last month, announced closing of $15 million initial public offering.

    Heart Test Laboratories, Inc. (NASDAQ:HSCS) shares fell 10.8% to $0.34 in pre-market trading after declining around 10% on Wednesday. There were no revenues for the first quarter of fiscal year 2024

    Seelos Therapeutics, Inc. (NASDAQ:SEEL) fell 10.1% to $0.2742 in pre-market trading after dipping 69% on Wednesday. Cantor Fitzgerald downgraded Seelos Therapeutics from Overweight to Neutral.

    36Kr Holdings Inc. (NASDAQ:KRKR) fell 10% to $0.9001 in pre-market trading after gaining 15% on Wednesday.

    Gaucho Group Holdings, Inc. (NASDAQ:VINO) fell 10% to $0.27 in pre-market trading.

    Elutia Inc. (NASDAQ:ELUT) fell 9.3% to $1.46 in pre-market trading. The company recently announced a $26 million private placement of 7,355,869 shares of common stock at $1.4275 per share.

    Now Read This: FedEx, FactSet Research And 3 Stocks To Watch Heading Into Thursday

    Get the next $AEHL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEHL
    $AENT
    $ARBB
    $AVGR

    CompanyDatePrice TargetRatingAnalyst
    Kezar Life Sciences Inc.
    $KZR
    10/17/2025$7.00Buy → Hold
    Jefferies
    Kezar Life Sciences Inc.
    $KZR
    10/17/2025Outperform → Mkt Perform
    William Blair
    Alliance Entertainment Holding Corporation
    $AENT
    10/6/2025$11.00Outperform
    Noble Capital Markets
    Alliance Entertainment Holding Corporation
    $AENT
    7/1/2025$10.00Buy
    Maxim Group
    Cardiol Therapeutics Inc.
    $CRDL
    6/2/2025$9.00Buy
    H.C. Wainwright
    Cardiol Therapeutics Inc.
    $CRDL
    1/28/2025$7.00Buy
    Rodman & Renshaw
    Cardiol Therapeutics Inc.
    $CRDL
    6/26/2024$10.00Buy
    ROTH MKM
    Cardiol Therapeutics Inc.
    $CRDL
    4/22/2024$9.00Buy
    H.C. Wainwright
    More analyst ratings

    $AEHL
    $AENT
    $ARBB
    $AVGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

    GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the

    2/25/26 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

    Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Members of management will present on March 4, 2026, at 10:30 a.m. EST.A live webcast of the Company's presentation, as well as a webcast replay will be available under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).About

    2/25/26 7:27:00 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

    BOSTON, Feb. 23, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a manuscript titled Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy in the journal Molecular Imaging and Biology. The paper, published February 19, 2026, reports on a novel tumor-selective immunotherapy approach that activates innate immune signaling specifically within cancer cells while enabling non-invasive imaging of drug delivery. The study was carried out in collaboration with Dr. Anna Moore, Professor, Dire

    2/23/26 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEHL
    $AENT
    $ARBB
    $AVGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rakin Kevin bought $74,200 worth of shares (70,000 units at $1.06), increasing direct ownership by 56% to 196,120 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 5:01:40 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $20,800 worth of shares (20,000 units at $1.04), increasing direct ownership by 20% to 118,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 8:43:47 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $31,800 worth of shares (30,000 units at $1.06), increasing direct ownership by 44% to 98,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    1/29/26 5:51:15 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEHL
    $AENT
    $ARBB
    $AVGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kezar Life Sciences downgraded by Jefferies with a new price target

    Jefferies downgraded Kezar Life Sciences from Buy to Hold and set a new price target of $7.00

    10/17/25 8:25:43 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences downgraded by William Blair

    William Blair downgraded Kezar Life Sciences from Outperform to Mkt Perform

    10/17/25 8:25:32 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Noble Capital Markets initiated coverage on Alliance Entertainment with a new price target

    Noble Capital Markets initiated coverage of Alliance Entertainment with a rating of Outperform and set a new price target of $11.00

    10/6/25 9:47:39 AM ET
    $AENT
    Durable Goods
    Consumer Discretionary

    $AEHL
    $AENT
    $ARBB
    $AVGR
    SEC Filings

    View All

    SEC Form 6-K filed by Cardiol Therapeutics Inc.

    6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)

    2/25/26 7:39:50 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TransCode Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    2/23/26 8:10:39 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Elutia Inc.

    SCHEDULE 13G/A - ELUTIA INC. (0001708527) (Subject)

    2/17/26 4:36:43 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEHL
    $AENT
    $ARBB
    $AVGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rakin Kevin bought $74,200 worth of shares (70,000 units at $1.06), increasing direct ownership by 56% to 196,120 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 5:01:40 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $20,800 worth of shares (20,000 units at $1.04), increasing direct ownership by 20% to 118,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 8:43:47 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $31,800 worth of shares (30,000 units at $1.06), increasing direct ownership by 44% to 98,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    1/29/26 5:51:15 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEHL
    $AENT
    $ARBB
    $AVGR
    Leadership Updates

    Live Leadership Updates

    View All

    Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™

    GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certified™ by Great Place to Work®, the leading organization that evaluates workplace culture through a standardized, anonymous employee survey methodology developed over 30 years of research. The certification recognizes organizations with high-trust workplace cultures, where sustained engagement and retention support consistent execution in regulated, innovation-driven industries. "Elutia isn't for everyone," said Dana Yoo, PhD, VP of Product Development. "The bar is high, and the work is hard. But

    2/18/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fitell Corporation Appoints AI and Robotics Executive Jack Zeng as Head of Technology at 2F Robotics to Accelerate Development and Commercialization Strategy

    Sydney, Australia, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Fitell Corporation (NASDAQ:FTEL) ("Fitell" or the "Company") announced today the appointment of Jack Zeng as the Head of Technology of 2F Robotics Pty Ltd, Fitell's robotics-focused subsidiary. Before joining Fitell, Mr. Zeng has founded and scaled successful technology ventures and brought experience in building data analytics and intelligent agent solutions for major enterprise customers including Fortune 500 across Asia, spanning product research and development, deployment, and go-to-market. With a background encompassing top-tier computer science education, Microsoft-certified engineering, and successful AI ventures, he has a track

    2/4/26 8:30:00 AM ET
    $FTEL
    Recreational Games/Products/Toys
    Consumer Discretionary

    Alliance Entertainment Appoints Jeffrey Smith as Senior Vice President of Sales and Marketing for Alliance Authentic™

    PLANTATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alliance Entertainment Holding Corporation (NASDAQ:AENT), the world's largest distributor of vinyl records and a leading curator of physical entertainment products and collectibles, today announced the appointment of Jeffrey Smith as Senior Vice President of Sales and Marketing for Alliance Authentic™, the company's newly launched premium platform for authenticated, numbered, investment-grade vinyl collectibles. Smith joins Alliance Authentic following a highly successful tenure as Vice President of Marketing at Discogs, the world's largest online marketplace for vinyl collectors. At Discogs, Smith played a central role in transforming t

    1/8/26 8:30:00 AM ET
    $AENT
    Durable Goods
    Consumer Discretionary

    $AEHL
    $AENT
    $ARBB
    $AVGR
    Financials

    Live finance-specific insights

    View All

    Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

    GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the

    2/25/26 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alliance Entertainment Reports Second Quarter Fiscal Year 2026 Results

    Adjusted EBITDA up 15% to $18.5M; Gross Margin expands 210 basis points to 12.8% Net Income increased to $9.4M, or $0.18 per share, compared to $7.1M, or $0.14 per share, in Q2 FY25 Strengthened balance sheet, ending quarter with $74.1M in working capital PLANTATION, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Alliance Entertainment Holding Corporation (NASDAQ:AENT), a premier distributor, logistics provider, and omnichannel fulfillment partner to the entertainment and pop culture collectibles industry, supplying more than 340,000 unique SKUs across music, video, video games, licensed merchandise, and exclusive collectibles to over 35,000 retail and e-commerce storefronts, reported it

    2/12/26 4:01:00 PM ET
    $AENT
    Durable Goods
    Consumer Discretionary

    Alliance Entertainment to Host Second Quarter Fiscal Year 2026 Results Conference Call on February 12 at 4:30 p.m. Eastern Time

    PLANTATION, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alliance Entertainment Holding Corporation (NASDAQ:AENT), a premier distributor, logistics provider, and omnichannel fulfillment partner to the entertainment and pop culture collectibles industry, supplying more than 340,000 unique SKUs across physical media, video games, toys, licensed merchandise, and exclusive collectibles to over 35,000 retail and e-commerce storefronts, will hold a conference call on Thursday, February 12, at 4:30 p.m. Eastern Time to discuss its results for the second quarter of fiscal year 2026 ended December 31, 2025. A press release detailing these results will be issued prior to the call. Alliance Entertainment

    1/29/26 8:30:00 AM ET
    $AENT
    Durable Goods
    Consumer Discretionary

    $AEHL
    $AENT
    $ARBB
    $AVGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by 36Kr Holdings Inc.

    SC 13G/A - 36Kr Holdings Inc. (0001779476) (Subject)

    11/15/24 9:42:24 AM ET
    $KRKR
    Real Estate